Tandem Diabetes Care, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Tandem Diabetes Care, Inc. (TNDM) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-06
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $0.00.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $0.00.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $75.22M.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $78.75M, a 153.71% increase from fiscal 2022.
- Tandem Diabetes Care, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $31.04M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $75.22M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $75.22M 10-Q · filed 2025-11-06 | $75.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $75.22M 10-Q · filed 2026-08-06 | $75.22M derived: sum of 3 quarters · filed 2026-08-06 | $75.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $75.22M 10-Q · filed 2026-05-07 | $75.22M derived: sum of 2 quarters · filed 2026-05-07 | $75.22M derived: sum of 3 quarters · filed 2026-05-07 | $75.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $78.75M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $78.75M 10-Q · filed 2024-11-06 | $78.77M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $78.75M 10-Q · filed 2024-08-01 | $78.77M derived: sum of 3 quarters · filed 2025-02-26 | $109.79M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $78.75M 10-Q · filed 2024-05-02 | $78.77M derived: sum of 2 quarters · filed 2025-02-26 | $109.79M derived: sum of 3 quarters · filed 2025-02-26 | $109.79M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $31.04M derived: sum of 2 quarters · filed 2025-02-26 | $31.04M derived: sum of 3 quarters · filed 2025-02-26 | $31.04M 10-K · filed 2025-02-26 |
| 2022-09-30 | $31.02M 10-Q · filed 2023-11-01 | $31.02M derived: sum of 2 quarters · filed 2023-11-01 | $31.02M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |